Jan. 29, 2013
LaserLock Technologies, Inc
. (OTC BB: LLTI), a global leader in providing state-of-the-art authentication solutions to pharmaceuticals, high-end retailers, casinos and governments, is pleased to announce the appointment of
as Chief Technology Officer. Donfried will support the company's overall mission of providing anti-counterfeiting and brand-protection product solutions. In addition he will also manage both internal and external IT.
"We are delighted to welcome Paul to LaserLock as the company enters its next phase of growth and evolution," said
, President of LaserLock Technologies. "Paul's leadership skills and proven talent have already had a positive impact on the authentication world. We are confident he will prove to be a talented addition to our company and help solve the most complex challenges in the anti-counterfeiting arena."
Donfried brings more than 20 years of experience in identity protection and authentication to LaserLock Technologies. His career includes nearly a decade of developing the SAFE-Biopharma Association, which focused on legally enforceable digital signatures for U.S. Food and Drug Administration (FDA) submissions. His work with the organization included developing and implementing a global enterprise I&AM infrastructure and a policy-driven, standards-based approach to global, legally enforceable digital signatures called SAFE.
"I am excited to be part of a team that brings to the table innovative and easy-to-use solutions that protect goods, brands, intellectual property and people," said
. "Counterfeiting poses a
threat and compromises the future of the global economy. I look forward to leveraging my IT experience and providing technical leadership to make a greater impact against the challenges we must overcome with anti-counterfeiting measures."
For the past three years, Donfried has served as Chief Technology Officer for Identity & Access Management at Verizon. Prior to joining Verizon, Donfried served as the Vice President for SAIC Identity & Access Management Solutions where he worked with some of the world's largest pharmaceutical companies.